^
Association details:
| Biomarker: | NRAS Q61R |
|---|---|
| Cancer: | Melanoma |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRAF mutation predicts sensitivity to MEK inhibition
Excerpt:
In contrast, PD0325901 treatment of SKMEL103 (NRAS(Q61R)), SKMEL30 (NRAS(Q61R)) and SKMEL31 (RAS/BRAF-WT) xenografts at a dose of 5 mg kg−1 only delayed tumour growth, with complete growth suppression requiring 25 mg kg−1 (Fig. 4b, c and Supplementary Fig. S3b; P < 0.01 for 5 versus 25 mg kg−1, and 5 and 25 mg kg−1 versus control).
DOI:
10.1038/nature04304
